ArcherDX at the Festival of Genomics London 2017
R. Kulesus | 12 Oct, 2016
January 31 - February 1, 2017
Sign up to get your free Archer wall calendar
at the event!
Get the poster!
The Festival of Genomics London brings together academia, biopharma and healthcare to explore the power of the genome in driving R&D and the diagnosis and treatment of disease into the future.
Stop by booth 73 to pick up a poster calendar and learn more about how Archer® Anchored Multiplex PCR (AMP™) enrichment chemistry harnesses the power of next-generation sequencing (NGS) for:
• Mutation analysis from liquid biopsies, solid tumors and blood cancers
• Immune repertoire profiling
• Cystic fibrosis mutation profiling
Attend the talk by Brian Kudlow, Ph.D., Vice President of R&D at ArcherDX
An Anchor in the Deep: Archer Reveal ctDNA for variant detection in liquid biopsies
31 Jan 2017 | 15:15 – 15:40
• The challenges of variant detection in ctDNA
• How innovative chemistry and software combine to overcome these challenges
• How open-ended fusion detection lead to the discovery of a novel, recurrent fusion in sarcomas
Brian Kudlow, Ph.D., is Vice President of Research and Development at ArcherDX, where he leads the development of chemistry and software tools to identify variants in FFPE and ctDNA and also to characterize the immune repertoire. Brian holds undergraduate degrees in mathematics and computer science and a Ph.D. in molecular and cellular biology. He has held both research and product development positions in a wide range of fields, including cancer biology, genetics, immunology, genome engineering, high-throughput screening and diagnostics. Outside of work, Brian is an avid rock climber and a mediocre guitar player.
Archer's newest assays
Reveal ctDNA Kit
Mutation profiling from circulating tumor DNA in liquid biopsies
The Archer® Reveal ctDNA™ 28 Kit for Illumina® is an advanced and user-friendly solution for targeted NGS of circulating cell-free tumor DNA e.g., ctDNA, ccfDNA, cfDNA from 28 genes commonly found mutated in solid tumor type cancers.
Immune repertoire sequencing assays
Archer® Immunoverse™ kits are targeted NGS assays to characterize the human immune repertoire from RNA input. Powered by AMP, the lyophilized kits uniquely tag and amplify V(D)J rearrangements for sequencing on Illumina® platforms.
VariantPlex CFTR Kit
Comprehensive mutation profiling for cystic fibrosis
The Archer® VariantPlex® CFTR kit is a targeted NGS assay for comprehensive detection of known and unknown variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
ArcherDX addresses the bottlenecks associated with using NGS by offering a robust platform for targeted sequencing applications. Archer target enrichment assays utilize AMP chemistry to generate highly enriched sequencing libraries for comprehensive profiling of fusions, CNVs, SNVs and indels. Amplification from independent, unidirectional primers and universal molecular barcoded adapters permit identification of novel gene fusions and mutations with nucleotide-level resolution. Requiring only one intact primer-binding site, AMP chemistry is uniquely suited to amplify small, degraded fragments, enabling solid tumor mutation profiling from FFPE samples and liquid biopsies. Archer’s easy-to-use, lyophilized kits generate sequencing-ready libraries from RNA, DNA, and liquid biopsy-derived ctDNA. Complemented by the Archer suite of assay design and bioinformatics analysis, Archer’s FusionPlex, VariantPlex and Reveal ctDNA assays facilitate complex mutation identification and discovery, while Immunoverse assays enable quantitative profiling of the expressed immune repertoire.